Kourti Malamati, Jiang Wen G, Cai Jun
Cardiff China Medical Research Collaborative (CCMRC), School of Medicine, Cardiff University, Heath Park, Cardiff CF14 4XN, UK.
Oxid Med Cell Longev. 2017;2017:9326454. doi: 10.1155/2017/9326454. Epub 2017 Feb 13.
Carbon monoxide (CO) has always been recognised as a toxic gas, due to its higher affinity for haemoglobin than oxygen. However, biological studies have revealed an intriguing role for CO as an endogenous signalling molecule, a gasotransmitter. CO is demonstrated to exert many cellular activities including anti-inflammatory, antiapoptotic, and antiproliferative activities. In animal studies, CO gas administration can prevent tissues from hypoxia or ischemic-reperfusion injury. As a result, there are a plethora of reports dealing with the biological applications of CO and CO-releasing molecules (CORMs) in inflammatory and vascular diseases. CORMs have already been tested as a therapeutic agent in clinical trials. More recently, an increased interest has been drawn to CO's potential use as an anticancer agent. In this review, we will aim to give an overview of the research focused on the role of CO and CORMs in different types of cancer and expand to the recent development of the next generation CORMs for clinical application in cancer treatment.
一氧化碳（CO）一直被认为是一种有毒气体，因为它对血红蛋白的亲和力高于氧气。然而，生物学研究揭示了CO作为一种内源性信号分子（一种气体递质）的有趣作用。已证明CO具有许多细胞活性，包括抗炎、抗凋亡和抗增殖活性。在动物研究中，给予CO气体可防止组织发生缺氧或缺血再灌注损伤。因此，有大量关于CO和CO释放分子（CORMs）在炎症和血管疾病中的生物学应用的报道。CORMs已在临床试验中作为治疗剂进行了测试。最近，人们对CO作为抗癌剂的潜在用途越来越感兴趣。在这篇综述中，我们旨在概述聚焦于CO和CORMs在不同类型癌症中的作用的研究，并扩展到用于癌症治疗临床应用的下一代CORMs的最新进展。
